Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Inpatient Versus Outpatient Hypomethylating Agent Induction for AML As a Predictor for Survival

Chetan Jeurkar, DO, Benjamin E Leiby, PhD, Joshua Banks, MS, Margaret Kasner, MDMSc, Gina Keiffer, MD, Lindsay Wilde, MD, Joanne Filicko-O'Hara, MD, Neil Palmisiano, MDMS

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-133837

Published: 2020

Journal Articles

Results of the Phase 1b Dose Escalation Study of OPB-111077, Decitabine, and Venetoclax for the Treatment of Newly Diagnosed or Relapsed/Refractory AML

Lindsay Wilde, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MDMS, Gina Keiffer, MD, Margaret Kasner, MDMSc

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-140729

Published: 2020

Journal Articles

Impact of Smoking and TP53 Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Xia Bi, MD MS, Zachary French, MD, Margaret Kasner, MDMSc, Gina Keiffer, MD, Lindsay Wilde, MD, Neil Palmisiano, MDMS

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-141640

Published: 2020

Journal Articles

Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML) Is Safe and Yields Healthcare Resource Savings

Gina Keiffer, MD, Kelly Hughes, Tingting Zhan, PhD, Lindsay Wilde, MD, Neil Palmisiano, MDMS, Margaret Kasner, MDMSc

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-140055

Published: 2020

Journal Articles

Vaccination Response after Autologous Stem Cell Transplantation

Onder Alpdogan, MD, Jennifer Hong, MD, Thomas R. Klumpp, MD, Abdullateef O Abdulkareem, MD MPH, Adam F. Binder, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Dolores Grosso, DNP, CRNP, Margaret Kasner, MDMSc, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MDMS, Lindsay Wilde, MD, Pierluigi Porcu, MD, Usama Gergis, MD, John L. Wagner, MD, Neal Flomenberg, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-141269

Published: 2020

Journal Articles

Socioeconomic Influences on the Treatment and Outcomes of Patients with Acute Myeloid Leukemia: Experience from an Urban Academic Center

Jonathan Pan, MD, Sushil Ghimire, MD, Molly Halloran, MD, Alexander Xu, BA, Tingting Zhan, PhD, Gina Keiffer, MD, Lindsay Wilde, MD, Neil Palmisiano, MDMS, Margaret Kasner, MDMSc, Adam F. Binder, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-143146

Published: 2020

Journal Articles

COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience

Lindsay Wilde, MD, Adam F. Binder, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, John L. Wagner, MD, Onder Alpdogan, MD, Margaret Kasner, MDMSc, Thomas R. Klumpp, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MDMS, Gina Keiffer, MD, Dolores Grosso, DNP, CRNP, Michael Millenson, Amy R. MacKenzie, MD, Allison Zibelli, MD, Neal Flomenberg, MD, Pierluigi Porcu, MD, Usama Gergis, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-140719

Published: 2020

Journal Articles

OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia

Lindsay Wilde, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MD MS, Margaret Kasner, MDMSc

Blood (2019) 134 (Supplement_1): 2597.

https://doi.org/10.1182/blood-2019-131979

Published: 2019

Journal Articles

A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)

Neil Palmisiano, MD, Grace Jeschke, PhD, Lindsay Wilde, MD, Benjamin E Leiby, PhD, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Dolores Grosso, DNP, CRNP, Thomas R. Klumpp, MD, Ubaldo Martinez Outschoorn, MD, John L Wagner, MD, Martin Carroll, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD, Alexander E. Perl, MD, Margaret Kasner, MD

Blood (2017) 130 (Supplement 1): 4267.

https://doi.org/10.1182/blood.V130.Suppl_1.4267.4267

Published: 2017

NARROW

Inpatient Versus Outpatient Hypomethylating Agent Induction for AML As a Predictor for Survival

Results of the Phase 1b Dose Escalation Study of OPB-111077, Decitabine, and Venetoclax for the Treatment of Newly Diagnosed or Relapsed/Refractory AML

Impact of Smoking and TP53 Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML) Is Safe and Yields Healthcare Resource Savings

Vaccination Response after Autologous Stem Cell Transplantation

Socioeconomic Influences on the Treatment and Outcomes of Patients with Acute Myeloid Leukemia: Experience from an Urban Academic Center

COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience

OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia

A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only